L E T T E R T O T H E E D I T O R
In psoriatic skin lesions, slanDC are detectable at high frequencies and are found to locally produce IL-23 and TNF-α. 1 Immature slanDC are present in blood, rapidly mature to high-level producers of the proinflammatory cytokines TNF-α, IL-1β, IL-6 and IL-23, and programme Th17 T cells. 
| QUESTIONS ADDRESSED
With this study, we asked for the regulatory effect of autocrine TNF-α, IL-1β and IL-6 for the production of IL-23 by slanDC. In this context, we also investigated the hierarchy among TNF-α, IL-1β and IL-6 in controlling each other's production.
| EXPERIMENTAL DESIGN
Detailed information can be found in the supplementary data.
| RESULTS
slanDC freshly purified from blood resemble immature DC, lack CD83 expression and fail to produce IL-23 after LPS stimulation.
Mature CD83 + slanDC can be obtained simply by culturing the cells for 6 hours. 4 Stimulating mature slanDC with the toll-like receptor 4 (TLR4) ligand LPS or the TLR7/8 ligand R848 induces strong IL-23 production. 4 Accordingly, in this study, we cultured slanDC prior to stimulation by LPS (Fig. S1 ). samples were collected after 6 or 12 hours ( Fig. 1 ). In accord with our previous studies, slanDC produced higher amounts of TNF-α compared to monocytes. Similar results were found when studying the IL-1β production. IL-6 production was detected early after stimulation and slanDC and monocytes produced similar amounts of IL-6
( Fig. 1 ). In cultures with slanDC, IL-23 was first detected 6 hours after stimulation and these levels further increased during the following hours of culture. In contrast to slanDC, monocytes produced only low amounts of IL-23 (Fig. 1 ).
In the next set of experiments, the early produced cytokines TNF-α, IL-1β, IL-6 were studied for their capacity to enhance IL-23 production. In addition, we asked for the regulatory role of IL-23. Therefore, antibodies specific for TNF-α (adalimumab), IL-1β (canakinumab), IL-6 receptor (tocilizumab) and IL-23p19 (Clone: HNU2319) were added at the start of the cultures. Expression of the respective cytokine F I G U R E 1 Kinetics of cytokine production by slanDC and monocytes. Precultured slanDC (mature) (a) and CD14 + monocytes (b) were stimulated (0 hour) with LPS (100 ng/mL; also see Fig. S1 ).
To reveal the dynamics and extent of the cytokine production, supernatants were obtained at indicated time points and cytokines were quantified by ELISA. Data are represented as means (+SEM) of triplicates of six donors. n.d., not detectable. Statistical differences were calculated using one-way ANOVA followed by Tukey's post-test. P<.05 was considered statistically significant (***P≤.001, **P≤.01, *P≤.05) | 315 receptors was verified as described in the supporting information,
Figs S2 and S3.
Targeting TNF-α in slanDC cultures stimulated with LPS significantly inhibited the production of IL-23 and IL-1β by 46% and 26%, respectively (Fig. 2) .
Neutralizing the proinflammatory cytokine IL-1β reduced the production of IL-23; however, this reduction was less pronounced when compared with the IL-23 inhibition achieved when TNF-α was targeted. Blocking either IL-1β or IL-23p19 did not alter the production of TNF-α, thereby providing evidence that TNF-α plays an important role for the autocrine stimulation of IL-23 production by slanDC.
Blocking IL-6 receptors with tocilizumab or neutralizing IL-23p19 was without significant effects on cytokines tested (Fig. 2) .
| CONCLUSIONS
IL-23 is of central importance for the pathogenesis of psoriasis.
It stimulates Th17 T-cell responses, and IL-23-targeting antibodies are very successfully tested in clinical studies. 3, 5 We previously reported on the strong IL-23 production by slanDC in psoriatic skin lesions and similarly, by slanDC purified from blood and stimulated in vitro. slanDC are also a rich source of the proinflammatory cytokines TNF-α, IL-1β and IL-6. We here asked for the relevance of autocrine TNF-α, IL-1β and IL-6 for the production of IL-23
by slanDC and also studied the regulatory hierarchy among these cytokines.
Stimulating slanDC in the presence of antibodies directed against TNF-α (adalimumab) reduced the IL-23 producing capacity by 46%, less pronounced effects were previously observed with recombinant
TNF-α receptors (etanercept).
6 IL-23 production by slanDC was also controlled by autocrine IL-1β, but appeared to be independent of IL-6. 
